No Benefit to Dual RAS Blockade in Meta-AnalysisNo Benefit to Dual RAS Blockade in Meta-Analysis

In fact, combined ACE-inhibitor and ARB therapy, given for a variety of disorders, was associated with increased risks of hyperkalemia, hypotension, and renal failure as well as drug withdrawal due to adverse effects. Researchers are hoping their results are the final nail in the coffin for dual RAS blockade. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news